Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

March 4, 2002

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Rheumatoid Arthritis
Interventions
DRUG

HuMax-CD4

HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.

DRUG

Placebo

Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.

DRUG

Humax-CD4

HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.

Trial Locations (54)

13210

One Crouse Medical Plaza, Syracuse

18015

East Pennsylvania Rheumatology, Bethlehem

19611

Clinical Research Center of Reading, West Reading

21740

Osteoporosis and Clinical Trials Center, Hagerstown

24153

Lewis Gayle Clinic, Salem

27609

C.A.R.E. Center, Raleigh

30033

nTouch Research, Decatur

33484

Arthritis Associates of South Florida, Delray Beach

33614

Tampa Medical Group Research, Tampa

33707

nTouch Research, St. Petersburg

34474

Ocala Rheumatology Research Center, Ocala

34996

Radiant Research, Inc., Stuart

40202

University of Louisville Hospital, Louisville

44406

DataPharm, Inc., Canfield

45219

Disease Study Group / Deaconess Hospital, Cincinnati

47714

West Pharmaceutical Services, Evansville

48910

Fiechtner Research, Lansing

49001

Midwest Arthritis Center, Kalamazoo

49503

Arthritis Education and Treatment Center, Grand Rapids

50322

Mercy Arthritis Center, Des Moines

53211

Medical Arts Center, Milwaukee

60061

Deerbrook Medical Associates, Vernon Hills

60068

Advocate Medical Group, Park Ridge

60611

North Western Center for Clinical Research, Chicago

60612

Rheumatology Associates, P.C., Chicago

62704

The Arthritis Center, Springfield

68114

Westroads Medical Group, Omaha

73112

Lynn Health Science, Oklahoma City

75231

Presbyterian Hospital of Dallas, Dallas

83642

Idaho Arthritis & Osteoporosis Center, Meridian Hills

84102

IHC Clinical Research Foundation, Salt Lake City

89502

Arthritis Center of Reno, Reno

91405

West Coast Clinical Research, Van Nuys

91730

Rheumatology & Internal Medicine, Boling Clinical Trials, Rancho Cucamonga

92108

Radiant Research, Inc., San Diego

92270

Advances in Medicine, Rancho Mirage

97213

Providence Arthritis Center, Portland

97225

Northwest Rheumatology Associates, PC, Portland

97504

Rheumatology Clinic, Medford

97701

Bend Memorial Clinic, Bend

98034

Evergreen Medical & Dental Center, Kirkland

98104

Minor & James Med., First Hill Medical Building, Seattle

98502

South Puget Sound Clinical Research Center, Olympia

98902

Internal Medicine Association of Yakima, Inc., P.S., Yakima

36111-2654

Rheumatology Associates, Montgomery

90813-3412

Pro Health Partners, Inc., Long Beach

06708

Arthritis Center of CT, Waterbury

02215

Beth Israel Deaconess Medical Center, Boston

16635-0909

Altoona Arthritis & Osteoporosis Center, Duncansville

23298-0647

Medical College of Virginia, Div. of Rheum., Richmond

R3C 3J5

CIADS, Medical Arts Building, Winnipeg

K1H 8L6

Ottawa Hospital-General Campus, Ottawa

M4N 3M5

Sunnybrook/Women's College Research Health Science Center, Toronto

H2L 1S6

Institute de Rhumtologie de Montreal, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genmab

INDUSTRY

NCT00042406 - Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker | Biotech Hunter | Biotech Hunter